Free tool
FAERS Monitor: Zituvimet Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216778 or its brand name (Zituvimet Xr, Metformin Hydrochloride, Sitagliptin). Reports on generic versions are filed under their own applications.
Reports
42
Serious
28
67% of reports
Hospitalization
11
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective6
- completed suicide4
- dizziness4
- nausea4
- pain in extremity4
- abnormal dreams3
- diarrhoea3
- malaise3
- somnolence3
- abdominal pain2
- anxiety2
- blood bilirubin increased2
- blood creatinine increased2
- blood glucose increased2
- decreased appetite2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 3 |
| 2011 | 13 |
| 2012 | 21 |
| 2025 | 1 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,117 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| abnormal dreamsSignal | 3 | 54.4 | 18.3 | 109 |
| blood bilirubin increased | 2 | 37.1 | 9.6 | 39 |
| completed suicideSignal | 4 | 24.0 | 9.5 | 67 |
| blood creatinine increased | 2 | 15.3 | 4.0 | 14 |
| somnolenceSignal | 3 | 7.5 | 2.5 | 11 |
| pain in extremitySignal | 4 | 6.8 | 2.7 | 15 |
| blood glucose increased | 2 | 5.3 | 1.4 | 3 |
| decreased appetite | 2 | 4.3 | 1.1 | 2 |
| abdominal pain | 2 | 4.3 | 1.1 | 2 |
| dizzinessSignal | 4 | 4.0 | 1.6 | 6 |
| anxiety | 2 | 3.5 | 0.9 | 2 |
| malaise | 3 | 3.4 | 1.2 | 3 |
| nausea | 4 | 2.5 | 1.0 | 2 |
| diarrhoea | 3 | 2.3 | 0.8 | 1 |
| drug ineffective | 6 | 2.3 | 1.1 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.